SG10201606950RA - Methods of administering beta7 integrin antagonists - Google Patents

Methods of administering beta7 integrin antagonists

Info

Publication number
SG10201606950RA
SG10201606950RA SG10201606950RA SG10201606950RA SG10201606950RA SG 10201606950R A SG10201606950R A SG 10201606950RA SG 10201606950R A SG10201606950R A SG 10201606950RA SG 10201606950R A SG10201606950R A SG 10201606950RA SG 10201606950R A SG10201606950R A SG 10201606950RA
Authority
SG
Singapore
Prior art keywords
methods
integrin antagonists
beta7 integrin
administering
administering beta7
Prior art date
Application number
SG10201606950RA
Inventor
Banmeet Anand
Byrne Sharon O'
Eric Stefanich
Meina Tang
Jennifer Visich
Marna Williams
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10201606950RA publication Critical patent/SG10201606950RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
SG10201606950RA 2011-03-31 2012-03-30 Methods of administering beta7 integrin antagonists SG10201606950RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470360P 2011-03-31 2011-03-31
US201161550216P 2011-10-21 2011-10-21

Publications (1)

Publication Number Publication Date
SG10201606950RA true SG10201606950RA (en) 2016-10-28

Family

ID=46931930

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201606950RA SG10201606950RA (en) 2011-03-31 2012-03-30 Methods of administering beta7 integrin antagonists
SG2013070925A SG193565A1 (en) 2011-03-31 2012-03-30 Methods of administering beta7 integrin antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013070925A SG193565A1 (en) 2011-03-31 2012-03-30 Methods of administering beta7 integrin antagonists

Country Status (15)

Country Link
US (1) US20140120084A1 (en)
EP (2) EP3412309A1 (en)
JP (3) JP6248029B2 (en)
KR (2) KR20130137688A (en)
CN (3) CN103608038A (en)
AR (1) AR085826A1 (en)
AU (2) AU2012236304C1 (en)
BR (1) BR112013023787A2 (en)
CA (1) CA2831732C (en)
IL (2) IL228078B (en)
MX (1) MX2013011130A (en)
MY (2) MY189494A (en)
RU (2) RU2016127812A (en)
SG (2) SG10201606950RA (en)
WO (1) WO2012135589A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY189494A (en) * 2011-03-31 2022-02-16 Genentech Inc Methods of administering beta7 integrin antagonists
UA116189C2 (en) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. FORMULATION FOR ANTI-α4β7 ANTIBODY
WO2014055824A1 (en) * 2012-10-05 2014-04-10 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
EP3933401A3 (en) * 2013-03-27 2022-04-13 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
JP2016538877A (en) * 2013-10-14 2016-12-15 シンアフィックス ビー．ブイ． Modified glycoproteins, protein conjugates and methods for their preparation
AR099856A1 (en) 2014-03-27 2016-08-24 Genentech Inc METHODS TO DIAGNOSE AND TREAT INFLAMMED INTESTINE DISEASE
CN113621027A (en) 2014-05-16 2021-11-09 领导医疗有限公司 Thioether peptide antagonists of alpha 4 beta 7 integrins
JP6904905B2 (en) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Predicting the outcome of treatment with anti-α4β7 integrin antibody
CN107257693A (en) * 2015-02-26 2017-10-17 豪夫迈·罗氏有限公司 Treat the integrin beta 7 antagonists and method of Crohn diseases
US20200093850A1 (en) * 2016-12-07 2020-03-26 Stelic Institute & Co., Inc. Pharmaceutical composition for treatment and prevention of chronic disease
WO2019078204A1 (en) * 2017-10-17 2019-04-25 富士フイルム株式会社 Medical image processing device and endoscope device
JP7365358B2 (en) 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド Antagonist of human integrin α4β7
WO2021076890A1 (en) 2019-10-16 2021-04-22 Morphic Therapeutic, Inc. INHIBITING HUMAN INTEGRIN α4β7
CA3166637A1 (en) * 2020-01-10 2021-07-15 Protagonist Therapeutics, Inc. Methods for treating inflammatory bowel diseases with .alpha.4.beta.7 integrin antagonists

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4256833A (en) 1979-01-08 1981-03-17 Majid Ali Enzyme immunoassay for allergic disorders
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A (en) 1988-04-28 1989-10-29 Univ Leland Stanford Junior RESEPTORDETERMINANTER I ANTI-T-CELLER FOER BEHANDLING AV AUTOIMMUNSJUKDOM.
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
EP0463101B2 (en) 1989-03-21 2003-03-19 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
WO1991001133A1 (en) 1989-07-19 1991-02-07 Arthur Allen Vandenbark T cell receptor peptides as therapeutics for autoimmune and malignant disease
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (en) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Heterogeneous conjugate antibody for treatment of HIV infection
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE297465T1 (en) 1991-11-25 2005-06-15 Enzon Inc METHOD FOR PRODUCING MULTIVALENT ANTIGEN-BINDING PROTEINS
DE69334351D1 (en) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetic binding protein for tumor markers
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
JP2003531178A (en) 2000-04-25 2003-10-21 アイデック ファーマスーティカルズ コーポレイション Intrathecal administration of rituximab for the treatment of central nervous system lymphoma
DK2336184T3 (en) * 2002-02-25 2015-02-16 Biogen Idec Inc Administration of agents for the treatment of inflammation.
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN101094868B (en) 2004-09-03 2013-07-10 健泰科生物技术公司 Humanized anti-beta7 antagonists and uses therefor
EP1805210A4 (en) * 2004-09-09 2007-10-24 Auckland Uniservices Ltd Novel peptides and methods for the treatment of inflammatory disease
TW200637857A (en) * 2005-01-14 2006-11-01 Bayer Healthcare Llc Water-soluble tetrazolium salts
UA94899C2 (en) * 2005-01-21 2011-06-25 Дженентек, Инк. Fixed dosing of her antibodies
RU2297835C1 (en) * 2005-09-26 2007-04-27 Закрытое акционерное общество "Партнер" Preparation for treatment of noninfectious inflammatory intestine diseases
WO2007110219A1 (en) * 2006-03-27 2007-10-04 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
MX2009011366A (en) * 2007-04-23 2009-11-05 Wyeth Corp Methods and compositions for treating and monitoring treatment of il-13-associated disorders.
WO2009140684A2 (en) * 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
WO2010009129A2 (en) * 2008-07-15 2010-01-21 Genentech, Inc. Methods of treating autoimmune diseases using cd4 antibodies
MY189494A (en) * 2011-03-31 2022-02-16 Genentech Inc Methods of administering beta7 integrin antagonists

Also Published As

Publication number Publication date
IL268822A (en) 2019-10-31
CN103608038A (en) 2014-02-26
JP2016155822A (en) 2016-09-01
US20140120084A1 (en) 2014-05-01
AR085826A1 (en) 2013-10-30
MY175332A (en) 2020-06-19
AU2012236304C1 (en) 2017-01-05
EP3412309A1 (en) 2018-12-12
EP2691113A1 (en) 2014-02-05
CN109734807A (en) 2019-05-10
MX2013011130A (en) 2013-10-30
RU2013148590A (en) 2015-05-10
IL228078B (en) 2019-09-26
MY189494A (en) 2022-02-16
CN114642731A (en) 2022-06-21
AU2012236304A1 (en) 2013-09-19
WO2012135589A1 (en) 2012-10-04
BR112013023787A2 (en) 2017-06-13
KR20130137688A (en) 2013-12-17
CA2831732A1 (en) 2012-10-04
AU2012236304B2 (en) 2016-03-24
JP2014515018A (en) 2014-06-26
RU2016127812A3 (en) 2020-01-24
IL228078A0 (en) 2013-09-30
KR20160105918A (en) 2016-09-07
CA2831732C (en) 2019-12-31
RU2016127812A (en) 2018-12-06
RU2595836C2 (en) 2016-08-27
JP6248029B2 (en) 2017-12-13
SG193565A1 (en) 2013-11-29
EP2691113A4 (en) 2014-12-24
JP2018154632A (en) 2018-10-04
KR102148063B1 (en) 2020-08-25
AU2016204185A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
HK1244183A1 (en) Deuterated derivatives of ivacaftor
IL228078A0 (en) Methods of administering beta7 integrin antagonists
IL232599A (en) Hydrobromide salt of pridopidine
IL232570A0 (en) New bicyclic dihydroisoquinoline-1-one derivatives
HUE047354T2 (en) Deuterated derivatives of ivacaftor
ZA201401577B (en) New bicyclic dihydroquinoline-2-one derivatives
EP2709991A4 (en) Use of cxcr4 antagonists
EP2790716A4 (en) Angiotensins for treatment of fibrosis
SG11201401287SA (en) Methods of treating liver conditions using notch2 antagonists
GB2497137B (en) Highly linear - gain oscillator
EP2694705A4 (en) Microfrabication of tunnels
HK1199040A1 (en) Use of antibody
IL226436A0 (en) Methods for the preparation of bendamustine
EP2684869A4 (en) Preparation of 3-mercaptopropionates
EP2804607A4 (en) Synthesis of raltegravir
EP2783690A4 (en) New use of neohesperidin
PL395425A1 (en) Preparation of 2-amino-N-tert-butyl-2-cyanoacetamide hydrochloride
GB201104632D0 (en) Use of medicament
PT2709991T (en) Use of cxcr4 antagonists
TWM433133U (en) Improvement of cosmetic container structure
GB201113308D0 (en) Characterisation of particles
TWM389587U (en) Structural improvement of nozzle
GB201113502D0 (en) Synthesis preparation and formation of shiphonated lirocene